Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 11/2005

01-11-2005 | Article

Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats

Authors: A. Tone, K. Shikata, M. Sasaki, S. Ohga, K. Yozai, S. Nishishita, H. Usui, R. Nagase, D. Ogawa, S. Okada, Y. Shikata, J. Wada, H. Makino

Published in: Diabetologia | Issue 11/2005

Login to get access

Abstract

Aims/hypothesis

Recent studies have shown that the inflammatory process is involved in the pathogenesis of diabetic nephropathy. Fourteen-membered ring macrolides, including erythromycin, have anti-inflammatory, as well as antibacterial effects. The aim of this study was to investigate the renoprotective effects of erythromycin in streptozotocin (STZ)-induced diabetic rats.

Methods

STZ-induced diabetic rats were treated orally with erythromycin (5 mg/kg body weight) or vehicle every day for 8 weeks. To evaluate the effect of erythromycin treatment, we measured urinary albumin excretion, and examined the following in the kidney: histological changes, the expression of intercellular adhesion molecule-1 (ICAM-1), macrophage infiltration, and nuclear factor-kappa B (NF-κB) activity.

Results

Erythromycin significantly reduced urinary albumin excretion without affecting blood glucose levels and blood pressure. Erythromycin also attenuated glomerular hypertrophy, mesangial expansion, macrophage infiltration and ICAM-1 expression in renal tissues. The expression of the gene encoding TGFB1 (also known as TGF-β1), type IV collagen protein production and NF-κB activity in renal tissues were increased in diabetic rats and reduced by erythromycin treatment.

Conclusions/interpretation

Erythromycin prevented renal injuries without changes of blood glucose levels and blood pressure in experimental diabetic rats. These results suggest that the renoprotective effects of erythromycin are based on its anti-inflammatory effect via suppression of NF-κB activation. Modulation of microinflammation with erythromycin may provide a new approach for diabetic nephropathy.
Literature
1.
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878CrossRefPubMed
2.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456–1462CrossRefPubMed
3.
Hiragushi K, Sugimoto H, Shikata K et al (2001) Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo- and micro-albuminuric patients with type 2 diabetes. Diabetes Res Clin Pract 53:149–159CrossRefPubMed
4.
Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL (1997) Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100:115–126PubMed
5.
Pugliese G, Pricci F, Romeo G et al (1997) Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 46:1881–1887PubMed
6.
Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ (1994) Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91:9436–9440PubMed
7.
Furuta T, Saito T, Ootaka T et al (1993) The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21:480–485PubMed
8.
Sassy-Prigent C, Heudes D, Mandet C et al (2000) Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49:466–475PubMed
9.
Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH (2004) Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 65:116–128CrossRefPubMed
10.
Hirata K, Shikata K, Matsuda M et al (1998) Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 41:185–192CrossRefPubMed
11.
Miyatake N, Shikata K, Sugimoto H et al (1998) Intercellular adhesion molecule 1 mediates mononuclear cell infiltration into rat glomeruli after renal ablation. Nephron 79:91–98CrossRefPubMed
12.
Sugimoto H, Shikata K, Hirata K et al (1997) Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 46:2075–2081PubMed
13.
Okada S, Shikata K, Matsuda M et al (2003) Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52:2586–2593PubMed
14.
Kadota Ji J (1996) Non-antibiotic effect of antibiotics. Clin Microbiol Infect 1(Suppl 2):S20–S22PubMed
15.
16.
17.
Miyajima M, Suga M, Nakagawa K, Ito K, Ando M (1999) Effects of erythromycin on experimental extrinsic allergic alveolitis. Clin Exp Allergy 29:253–261CrossRefPubMed
18.
Li Y, Azuma A, Takahashi S et al (2002) Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice. Chest 122:2137–2145CrossRefPubMed
19.
Azuma A, Furuta T, Enomoto T et al (1998) Preventive effect of erythromycin on experimental bleomycin-induced acute lung injury in rats. Thorax 53:186–189PubMed
20.
Usui H, Shikata K, Matsuda M et al (2003) HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18:265–272CrossRefPubMed
21.
Guijarro C, Egido J (2001) Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 59:415–424CrossRefPubMed
22.
Kato S, Luyckx VA, Ots M et al (1999) Renin–angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 56:1037–1048CrossRefPubMed
23.
Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T (1997) Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappa B sites and NF-kappa B/Rel subunit specificity. J Biol Chem 272:31092–31099CrossRefPubMed
24.
Lee FT, Cao Z, Long DM et al (2004) Interactions between angiotensin II and NF-kappa B-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 15:2139–2151CrossRefPubMed
25.
Mezzano SA, Ruiz-Ortega M, Egido J (2001) Angiotensin II and renal fibrosis. Hypertension 38:635–638PubMed
26.
Benigni A, Remuzzi G (2001) How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis 37:S21–S24PubMed
27.
Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J (2001) Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappa B and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol 158:1743–1756PubMed
28.
Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY (2003) Role of TGF-beta signalling in extracellular matrix production under high glucose conditions. Kidney Int 63:2010–2019CrossRefPubMed
29.
Gruden G, Setti G, Hayward A et al (2005) Mechanical stretch induces monocyte chemoattractant activity via an NF-kappa-B-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol 16:688–696CrossRefPubMed
30.
Mezzano S, Aros C, Droguett A et al (2004) NF-kappa B activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19:2505–2512CrossRefPubMed
31.
Panchapakesan U, Pollock CA, Chen XM (2004) The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. Am J Physiol Renal Physiol 287:F528–F534CrossRefPubMed
32.
Panchapakesan U, Sumual S, Pollock CA, Chen X (2005) PPAR gamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 10 (in press)
33.
Hoffman BB, Sharma K, Zhu Y, Ziyadeh FN (1998) Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int 54:1107–1116CrossRefPubMed
34.
Riser BL, Cortes P, Yee J et al (1998) Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF-beta. J Am Soc Nephrol 9:827–836PubMed
35.
Yasuda T, Kondo S, Homma T, Harris RC (1996) Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells. J Clin Invest 98:1991–2000PubMed
36.
Ishida T, Haneda M, Maeda S, Koya D, Kikkawa R (1999) Stretch-induced overproduction of fibronectin in mesangial cells is mediated by the activation of mitogen-activated protein kinase. Diabetes 48:595–602PubMed
37.
Utimura R, Fujihara CK, Mattar AL et al (2003) Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63:209–216CrossRefPubMed
38.
Enomoto F, Kin R, Kataoka T et al (2003) Modulation of neutrophil adhesion to vascular endothelial cells in rat experimental otitis media treated with a macrolide. Auris Nasus Larynx 30:247–251CrossRefPubMed
39.
Iino Y, Toriyama M, Kudo K, Natori Y, Yuo A (1992) Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol (Suppl) 157:16–20
40.
Fujii T, Kadota J, Morikawa T et al (1996) Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells. Antimicrob Agents Chemother 40:1548–1551PubMed
41.
Ren W, Li XH, Chen BD, Wooley PH (2004) Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappa B activity. J Orthop Res 22:21–29CrossRefPubMed
42.
Wallwork B, Coman W, Mackay-Sim A, Cervin A (2004) Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis. Laryngoscope 114:286–290CrossRefPubMed
43.
Ichiyama T, Nishikawa M, Yoshitomi T et al (2001) Clarithromycin inhibits NF-kappa B activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 45:44–47CrossRefPubMed
44.
Kikuchi T, Hagiwara K, Honda Y et al (2002) Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 49:745–755CrossRefPubMed
45.
Sharma K, Jin Y, Guo J, Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522–530PubMed
Metadata
Title
Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats
Authors
A. Tone
K. Shikata
M. Sasaki
S. Ohga
K. Yozai
S. Nishishita
H. Usui
R. Nagase
D. Ogawa
S. Okada
Y. Shikata
J. Wada
H. Makino
Publication date
01-11-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1945-6

Other articles of this Issue 11/2005

Diabetologia 11/2005 Go to the issue

Short communication

Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia

Article

Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat

Article

Hypothalamic pro-opiomelanocortin gene delivery ameliorates obesity and glucose intolerance in aged rats

Article

Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?

Article

β-Adrenoceptors, but not α-adrenoceptors, stimulate AMP-activated protein kinase in brown adipocytes independently of uncoupling protein-1

Editorial

Latent autoimmune diabetes in adults: a guide for the perplexed
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits